Swedish Orphan Biovitrum (Sobi) announced that the rare disease drug maker’s phase 3 study of avatrombopag did not meet the clinical trial’s primary endpoint, sending the company’s shares sharply down.

Shares of Dova Pharmaceuticals were up more than 38 percent after Sweden-based Sobi announced the intended acquisition of the North Carolina-based company for $915 million.